Precision Medicine for Indolent Systemic Mastocytosis (PRISM)
ConditionSystemic Mastocytosis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
This study is being done to better understand how symptoms of Systemic Mastocytosis (SM) relate to biological signals and to better understand how different treatments affect these signals.
Eligibility criteria
Qualifiers
Diagnosis of indolent systemic mastocytosis as defined by the World Health Organization 2022 criteria.
Doses of baseline treatment medications are stable for ≥ 14 days prior to enrollment.
Patient must have an Eastern Cooperative Oncology Group Performance Status of 0 to 2.
Disqualifiers
Diagnosis of advanced systemic mastocytosis defined by established criteria as outlined by the World Health Organization 2022 criteria.
Patient must not have had any cytoreductive therapy including but not limited to cladribine, interferon alpha, pegylated interferon, or antibody therapy < 28 days prior to enrollment.
Any other significant medical issue as determined by the principal investigator.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
25 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov